Drug intelligence / Profile preview

pan-flu multivariant mucosal vaccine

Development stage: Preclinical
Lead developer: TFF Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Mucosal

Overview

The pan-flu multivariant mucosal vaccine is a universal influenza vaccine developed by TFF Pharmaceuticals in collaboration with Dr. Ted Ross's lab at the Cleveland Clinic. It is formulated as a shelf-stable, dry powder using TFF's patented Thin Film Freezing (TFF) technology, eliminating the need for cold-chain storage. This vaccine aims to be over 75% effective against symptomatic influenza and provide protection against both group I and II influenza A viruses, addressing limitations of current seasonal flu vaccines and improving global accessibility.

Beyond the preview

Go deeper on pan-flu multivariant mucosal vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pan-flu multivariant mucosal vaccine.

Explore the full profile